318 related articles for article (PubMed ID: 26044975)
1. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
Sullivan LC; Clarke WP; Berg KA
Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
[TBL] [Abstract][Full Text] [Related]
2. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
3. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
4. A new class of 5-HT
Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
[TBL] [Abstract][Full Text] [Related]
5. 5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists.
Harmon JL; Wills LP; McOmish CE; Demireva EY; Gingrich JA; Beeson CC; Schnellmann RG
J Pharmacol Exp Ther; 2016 Apr; 357(1):1-9. PubMed ID: 26787771
[TBL] [Abstract][Full Text] [Related]
6. Morphine-induced Straub tail reaction in mice treated with serotonergic compounds.
Belozertseva IV; Dravolina OA; Tur MA; Semina MG; Zvartau EE; Bespalov AY
Eur J Pharmacol; 2016 Nov; 791():1-7. PubMed ID: 27565217
[TBL] [Abstract][Full Text] [Related]
7. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin exhibits serotonin 5-HT
Muneta-Arrate I; Diez-Alarcia R; Horrillo I; Meana JJ
Eur Neuropsychopharmacol; 2020 Jul; 36():83-89. PubMed ID: 32517960
[TBL] [Abstract][Full Text] [Related]
9. Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT2C receptor inverse agonism and agonism.
Graves SM; Clark MJ; Traynor JR; Hu XT; Napier TC
Neuropharmacology; 2015 Feb; 89():113-21. PubMed ID: 25229719
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT
Albujuq NR; Meana JJ; Diez-Alarcia R; Muneta-Arrate I; Naqvi A; Althumayri K; Alsehli M
J Med Chem; 2023 Jul; 66(13):9057-9075. PubMed ID: 37378639
[TBL] [Abstract][Full Text] [Related]
11. Signalling profile differences: paliperidone versus risperidone.
Clarke WP; Chavera TA; Silva M; Sullivan LC; Berg KA
Br J Pharmacol; 2013 Oct; 170(3):532-45. PubMed ID: 23826915
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel 1-
Mao Q; Zhang B; Li W; Tian S; Shui W; Ye N
ACS Chem Neurosci; 2020 Feb; 11(4):549-559. PubMed ID: 31968160
[TBL] [Abstract][Full Text] [Related]
13. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
14. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
15. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
Meltzer HY; Massey BW; Horiguchi M
Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
[TBL] [Abstract][Full Text] [Related]
16. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
17. Receptor mechanisms in the treatment of schizophrenia.
Reynolds GP
J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
[TBL] [Abstract][Full Text] [Related]
18. Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT
Aringhieri S; Kolachalam S; Gerace C; Carli M; Verdesca V; Brunacci MG; Rossi C; Ippolito C; Solini A; Corsini GU; Scarselli M
Eur Neuropsychopharmacol; 2017 Apr; 27(4):383-398. PubMed ID: 28283227
[TBL] [Abstract][Full Text] [Related]
19. Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action.
Mocci G; Jiménez-Sánchez L; Adell A; Cortés R; Artigas F
Neuropharmacology; 2014 Apr; 79():49-58. PubMed ID: 24211653
[TBL] [Abstract][Full Text] [Related]
20. 5-HT2C receptor modulators: a patent survey.
Lee J; Jung ME; Lee J
Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
